Rite Aid Can’t Get It Right (RAD, CVS, WAG)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rite Aid Corp. (NYSE: RAD) is indicated to open lower after the company posted another net loss for the quarter. It also lowered guidance for a second time. We just noted this one as a turnaround stock that has yet to turn around, and this proves that even more true.
Its $93 million net loss came in at -$0.12 EPS, while First Call was looking for only -$0.07 EPS targets. revenues came in at $6.52 Billion, also under the $6.6 Billion estimate. To top it off, Rite Aid said a slow cold and flu season was having an impact.
As far as guidance, that is lower. It now expects to lose $161 to $192 million for fiscal 2008, a wider loss than its prior range of $78 to $161 million. It targets fiscal 2008 sales between $24.3 and $24.6 billion, under the September forecast of $24.5 to $25.1 billion.
Last night Jim Cramer noted the difference on execution between CVS Caremark (NYSE:CVS) and Walgreens (NYSE:WAG) with CVS being the clear winner. Imagine what you’d have to say about the execution here. This one had been one of Cramer’s Top 9 Picks for 2007, but its turnaround stumbled. Hell, it’s falling off the cart.
Rite Aid shares are now indicated down almost 10% at $3.70 in crummy pre-market trading. Its 52-week trading range is $3.44 to $6.74. That hurts.
Jon C. Ogg
December 20, 2007
Join our open email distribution list to hear about many special situation previews covering IPO’s, spin-offs, reorganizations, and more.
Contact [email protected] for any questions or corrections.

